← Back to Clinical Trials
Recruiting NCT06657846
HRQoL and Financial Toxicity in Patients With VEXAS Syndrome
Trial Parameters
Condition VEXAS
Sponsor Gruppo Italiano Malattie EMatologiche dell'Adulto
Study Type OBSERVATIONAL
Phase N/A
Enrollment 100
Sex ALL
Min Age 18 Years
Max Age 99 Years
Start Date 2024-11-01
Completion 2025-06-10
Brief Summary
This multicenter cross-sectional observational study aims to describe health-related quality of life (HRQoL) and symptom profiles of patients with VEXAS syndrome.
Eligibility Criteria
Inclusion Criteria: * Adult patients (≥ 18 years old) with a confirmed diagnosis of VEXAS syndrome (UBA1 pathogenic mutation detected) * Written informed consent Exclusion Criteria: * \- Having any kind of psychiatric disorder or major cognitive dysfunction. * Not able to read and understand local language